Clinical Trial Update: A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety and pharmacokinetics of XMAB24306 in combination with Daratumumab for relapsed/refractory multiple myeloma; the trial status is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Daratumumab (daratumumab)
• XMAB24306

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED